Department of Cardiology, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Istanbul, Turkey.
Department of Cardiology, Sultan II. Abdülhamid Han Training and Research Hospital, Istanbul, Turkey.
Indian Heart J. 2022 Mar-Apr;74(2):127-130. doi: 10.1016/j.ihj.2022.01.003. Epub 2022 Jan 31.
Implantable cardioverter defibrillators (ICD) are recommended in heart failure with reduced ejection fraction (HFrEF) patients to reduce arrhythmic deaths. This study aimed to identify risk factors associated with mortality within one-year following the ICD. The data from our hospital's electronic database system was extracted for patients who were implanted ICD secondary to HFrEF between 2009 and 2019. Overall, 1107 patients were included in the present analysis. Mortality rate at one-year following the device implantation was 4.7%. In multivariate analysis; age, atrial fibrillation, New York Heart Association classification >2, blood urea nitrogen, pro-brain natriuretic peptide and albumin independently predicted one year mortality.
植入式心脏复律除颤器(ICD)被推荐用于射血分数降低的心力衰竭(HFrEF)患者,以降低心律失常性死亡。本研究旨在确定与 ICD 植入后一年内死亡率相关的危险因素。从我们医院的电子数据库系统中提取了 2009 年至 2019 年因 HFrEF 植入 ICD 的患者的数据。共有 1107 例患者纳入本分析。装置植入后一年的死亡率为 4.7%。多变量分析中;年龄、心房颤动、纽约心脏协会分级>2、血尿素氮、脑利钠肽前体和白蛋白独立预测一年死亡率。